|
[1]
|
中国抗癌协会泌尿男生殖系肿瘤专业委员.2018版转移性前列腺癌诊治中国专家共识[J].中华外科杂志, 2018, 56(9):646-652. http://d.old.wanfangdata.com.cn/Periodical/zhwk201809002
|
|
[2]
|
中国抗癌协会泌尿肿瘤专业委员会.中国去势抵抗性前列腺癌诊治专家共识[J].中华外科杂志, 2016, 54(7):481-484. http://d.old.wanfangdata.com.cn/Periodical/zhwk201607001
|
|
[3]
|
Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer[J]. N Engl J Med, 2018, 378(26):2465-2474. http://cn.bing.com/academic/profile?id=98b53741cf31b6a31f83cdbbf0c4295d&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[4]
|
Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer[J]. N Engl J Med, 2018, 378(15):1408-1418. http://cn.bing.com/academic/profile?id=8f531bf2df20a1c40e0ee6dcebd56d2f&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[5]
|
Small EJ, Saad F, Chowdhury S, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer[J]. Ann Oncol, 2019, 30(11):1813-1820. http://cn.bing.com/academic/profile?id=615c3705f2b5e9cfab3ba92182ec75bb&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[6]
|
Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer[J]. N Engl J Med, 2019, 380(13):1235-1246. http://cn.bing.com/academic/profile?id=13ddad329b4b38acf3b83f40fc4e2f6f&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[7]
|
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer[J]. N Engl J Med, 2004, 351(15):1513-1520. doi: 10.1056-NEJMoa041318/
|
|
[8]
|
Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial[J]. Ann Oncol, 2013, 24(9):2402-2408. http://cn.bing.com/academic/profile?id=fa31b87bf405b2295c941822f4e3a61e&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[9]
|
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer[J]. N Engl J Med, 2011, 364(21):1995-2005. http://d.old.wanfangdata.com.cn/Periodical/zhmnwk201805010
|
|
[10]
|
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy[J]. N Engl J Med, 2013, 368(2):138-148. http://cn.bing.com/academic/profile?id=e5c16672c75956c4b407f161097abd59&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[11]
|
Beer TM, Armstrong AJ, Rathkop DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy[J]. N Engl J Med, 2014, 371(5):424-433. http://cn.bing.com/academic/profile?id=748de7134622995fa0e1db8737c2336f&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[12]
|
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy[J]. N Engl J Med, 2012, 367(13):1187-1197. http://cn.bing.com/academic/profile?id=73f746f1dc51cbb9707851293ef3d398&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[13]
|
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. N Engl J Med, 2010, 363(5):411-422. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_3283534
|
|
[14]
|
Gulley JL, Borre M, Vogelzanget NJ, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration resisitant prostate cancer[J]. J Clin Oncol, 2019, 37(13):1051-1061.. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=3a1f017c405fa1d205d09558229eb46e
|
|
[15]
|
Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer:multicohort, open-label phase II KEYNOTE-199 study[J]. J Clin Oncol, 2020, 38(5):395-405. http://cn.bing.com/academic/profile?id=f55cc60f53899034f0b15c9069eafeb9&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[16]
|
Julie NG, Emmanuel SA, Christopher JH, et al. Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castrationresistant prostate cancer (mCRPC):KEYNOTE-199 cohorts 4-5[J]. J Clin Oncol, 2020, 38(6_suppl):15. https://www.researchgate.net/publication/339387660_Pembrolizumab_pembro_plus_enzalutamide_enza_for_enza-resistant_metastatic_castration-resistant_prostate_cancer_mCRPC_KEYNOTE-199_cohorts_4-5
|
|
[17]
|
Hussain M, Mateo J, Fizazi K, et al. Profound:phase Ⅲ study of olaparib versus enzalutamide or abiraterone for metastatic castrationresistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations[J]. Ann Oncol, 2019, 30(Suppl 5):LAB12. http://d.old.wanfangdata.com.cn/Periodical/hsjyxyxb201202013
|
|
[18]
|
Marshall CH, Sokolova AO, McNatty AL, et al. Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations[J]. Eur Urol, 2019, 76(4):452-458. http://cn.bing.com/academic/profile?id=7736ff53a094e96ed5e5c9f5e69a8660&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[19]
|
Ratta R, Guida A, Scotté F, et al. PARP inhibitors as a new therapeutic option in metastatic prostate cancer:a systematic review[J]. Prostate Cancer Prostatic Dis, 2020[Epub ahead of print]. doi: 10.1038/s41391-020-0233-3
|
|
[20]
|
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer[J]. N Engl J Med, 2013, 369(3):213-223. http://cn.bing.com/academic/profile?id=368ba25768b1d0f0cc1078ea7f97941d&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[21]
|
Hofman MS, Violet J, Hicks RJ, et al. 177Lu-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial):a single-centre, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19(6):825-833. https://www.ncbi.nlm.nih.gov/pubmed/29752180
|
点击查看大图
下载:
